Volume : 6, Issue : 3, March - 2017
INTRAVENOUS FERRIC CAROXYMALTOSE FOR ANAEMIA IN PREGNANCY
Dr. Rekhalatha, Dr. Yogesh Bangera
Abstract :
<p> <span style="font-size: 20pt;">Background: Iron deficiency is a very common nutritional deficiency amongst women of reproductive age. Peripartum iron deficiency anaemia (IDA) is associated with significant maternal, fetal and infant morbidity. Currently for treatment are limited: these include oral iron supplementation, which can be ineffective and poorly tolerated, and red blood cell transfusions, which carry an inherent risk and should be avoided. Ferric carboxymaltose is</span><span style="font-size: 20pt;"> </span><span style="font-size: 20pt;">new treatment option that may be better tolerated.</span></p> <p class="BodyA"><span style="font-size:20.0pt;line-height:115%">The study designed to assess the safety and efficacy of iron deficiency anaemia (IDA) correction with intravenous ferric carboxymaltose in pregnant women with mild, moderate and severe anaemia in pregnancy.<o:p></o:p></span></p> <p class="BodyA"><span style="font-size:20.0pt;line-height:115%">Methods: retrospective observational study; 43 anaemic pregnant women received ferric carboxymaltose up to 15 mg/kg between 24 and 40 weeks of pregnancy . Treatment effectiveness was assessed by repeat haemoglobin (Hb) and serum ferritin measurements and patient report of well-being at3rd week. Safety was assessed by analysis of adverse drug reactions and fetal heart rate monitoring during the infusion.<o:p></o:p></span></p> <p class="BodyA"><span style="font-size:20.0pt;line-height:115%">Results: Intravenous ferric carboxymaltose infusion significantly increased Hb values (p < 0.01) above baseline levels in all women. Increased Hb values were observed at 1and 3 weeks post infusion a. Ferritin values increased significantly after the infusion. Fetal heart rate monitoring did not indicate a drug related negative impact on the fetus. Follow-up interview during revisit was conducted on 43 (100%) women at3weeks. Of these women, 35 (81.3%) reported an improvement in their wellbeing (48% reported feeling “much better”, 15% reported “a little better”, and 8(18) reported feeling “</span><span lang="IT" style="font-size:20.0pt;line-height:115%;mso-ansi-language:IT">no different</span><span style="font-size:20.0pt;line-height:115%">”) after the infusion. None of the women re- ported feeling worse.<o:p></o:p></span></p> <p class="BodyA"><span style="font-size:20.0pt;line-height:115%"> </span></p> <p class="BodyA"><span style="font-size:20.0pt;line-height:115%">Conclusions: Our retrospective data is consistent with existing observational reports of the safe and effective use of ferric carboxymaltose in the treatment of iron deficiency anaemia in pregnancy.<o:p></o:p></span></p>
Keywords :
Article:
Download PDF Journal DOI : 10.15373/2249555XCite This Article:
Dr. Rekhalatha, Dr. Yogesh Bangera, INTRAVENOUS FERRIC CAROXYMALTOSE FOR ANAEMIA IN PREGNANCY, GLOBAL JOURNAL FOR RESEARCH ANALYSIS : Volume-6, Issue-3, March‾2017